Neurology Research

DELOS

  • Principal Investigators:
    • Susan Iannaccone, MD
    • Michael Dowling, MD, PhD
  • For more information, contact:
    • Myriam Iglewski, PhD (214) 456-2683
  • A phase III Double Blind, Randomized Placebo-Controlled Study of the efficacy, Safety and Tolerability of Idebenone in 10-18 year old patients with Duchenne Muscular Dystrophy
  • Patients are randomized to control/placebo or study drug/ Idebenone 900mg per day. Primary Endpoints of this clinical trial include 1) Assessing the efficacy of Idebenone compared to placebo in improving respiratory and cardiac function in patient with DMD, 2) Assessing the efficacy of Idebenone compared to placebo in improving skeletal muscle strength and motor function in patients with DMD, and 3) Assessing the efficacy of Idebenone, compared to placebo in improving quality of live and safety/tolerability for patients with DMD
  • This study recruits patients with Duchenne Muscular Dystrophy between the ages of 10 and 18 years of age

Patent Foramen Ovale in Stroke in Sickle Cell Disease (PFAST)

  • Principal Investigators:
    • Susan Iannaccone, MD
    • Michael Dowling, MD, PhD
  • For more information, contact:
    • Patricia Plumb, RN (214) 456-6761
  • Comparing the incidence of Patent Foramen Ovale (PFO) in children with sickle cell disease and stroke versus children without sickle cell disease
  •  An echocardiogram is completed with saline injections via intravenous line (IV) to detect a PFO
  • You are eligible if you have an IV placed for other reason besides research, between the ages of 2-19 without known heart disease or a past medical history of a stroke